of the IFNβ (ChIFN2) promoter as effectively as parental FWPV, but the mutant 52 was more sensitive to exogenous ChIFN1. Therefore, unlike the related protein 53 fpv012, fpv014 does not contribute to the FWPV block to induction of ChIFN2, 54 but does confer resistance to an established antiviral state. 55
INTRODUCTION 56
The major mammalian innate host response to virus infection is the type I 57 interferon (IFN) system, consequently many viruses have evolved mechanisms 58 to evade or subvert it (1, 2). The prototypic mammalian poxvirus, vaccinia virus 59 (VACV), encodes a number of proteins that have been shown to modulate the IFN 60 system in diverse ways (reviewed by Perdiguero et al. (3) ). They include double-61 stranded (ds) RNA-binding protein E3 (4), eIF-2α mimic K3 (5), soluble IFN 62 receptor mimic B18 (6, 7), Stat phosphorylation inhibitor H1 (8) (such as E3L, K3L and B18R), with the exception of an ortholog of H1 (12). The 71 lack of E3L and K3L is a feature not unique to avipoxviruses -they are also 72 absent from the now only remaining extant human poxvirus, molluscum 73 contagiosum virus, which causes chronic infection (13). Avipoxviruses also lack 74 members, several of which are immunomodulatory (14) (15) (16) (17) (18) (19) (20) , of the family of 75 proteins found in VACV that share a structural fold with host apoptosis-76
controlling . Avipoxviruses do encode potential orthologs of 77 immunoregulators less frequently found in mammalian poxviruses, such as the 78 IL-10 analogue encoded by CNPV ((11) and found in mammalian poxviruses 79 other than VACV, e.g. Orf virus (21)) and TGF-β orthologs found initially in FWPV 80 (10) and CNPV (11) then subsequently in deerpox virus (22) . Ligand-binding 81 studies have also identified a binding protein for chicken IFN-γ, distinct from 82
IFN-γ-binding proteins encoded by mammalian poxviruses (23). 83 84
We show here that FWPV is highly resistant to chicken type I IFN (ChIFN), 85 considerably more so than the artificially chicken cell-adapted strain of VACV, 86 modified virus Ankara (MVA) and that the resistance is due to FWPV encoded 87 protein(s). We have used a broad-scale genetic screen to search for modulators, 88 The ChIFN2 promoter reporter (pChIFN2lucter (28)) and the constitutive β-123 galactosidase reporter plasmid (pJATlacZ (29)) have been previously described, 124 as has pEFPlink2, which uses the elongation factor Iα promoter to direct high 125 levels of expression of cloned cDNAs, as originally described by Marais et al. (30) . were transfected with poly(I:C) (10µg/ml) using Polyfect (Qiagen) or 136
Lipofectamine (Invitrogen), as described by Childs et al. (28) , and incubated for 137 16 hours. Luciferase assays were carried out and data were normalised using β-138 galactosidase measurements. 139
140

Chicken IFN-α 141
Preliminary studies were undertaken using recombinant chicken IFN-α (ChIFN1, 142 (31), P. Staeheli, University of Freiburg, Germany). Subsequently the ChIFN1 143 gene was amplified from CEF DNA by PCR and cloned it into pEFPlink2 using 144
NcoI and XbaI sites. This plasmid was transfected into 293 cells (9cm plate); the 145 supernatant, collected after 48 h incubation, was centrifuged to remove cell 146 debris and was titrated by 50% plaque reduction assay (32) using SFV A7(74) on 147
CEF. 148 149
Construction of FWPV-chimeric MVA 150
The approach adopted, after considerable optimisation of the individual steps, 151 involved using Splice-Overlap-Extension (SOE) PCR to assemble 10 kbp linear 152 recombination templates from four constituent parts: (i) 8 (or 4 kbp) PCR 153 fragments of the FWPV genome (amplified using high fidelity Taq polymerase), 154 flanked to the left by (ii) MVA sequences (20406 to 20894), to the proximal right 155 by (iii) a VACV p7.5 promoter upstream of the E. coli gpt gene and to the distal 156 right by (iv) MVA sequences (20916 to 21472). Parts (iii) and (iv) were pre-157 assembled by SOE PCR before assembly of the complete linear recombination 158 template from the resulting three components. The templates were purified by 159 agarose gel electrophoresis, where crystal violet was used as the stain, rather 160 than ethidium bromide, to avoid UV damage to the long templates. 161
162
The assembled FWPV genomic DNA selection cassettes were transfected into DF-163 1 cells previously infected with an MVA recombinant, MVA-LZ (which carries the 164 E. coli lacZ gene inserted into the MVA thymidine kinase locus under control of 165 the VACV p11 promoter to facilitate plaque identification by staining for β-166 galactosidase). Recovered viruses were bulk passaged three times in CEF under 167 mycophenolic acid selection (in the presence of xanthine and hypoxanthine) for 168 the gpt gene. Viral genomic DNA was then extracted and analysed by PCR to 169 confirm recombination of the FWPV genomic insert and loss of parental virus. 170
Internal primers for the overlapping FWPV fragments were used for 171 recombinant-specific PCR, together with MVA flanking primers to detect the 172 presence of residual parental virus (the larger recombinant-specific product 173 being product out-competed by any smaller parental-specific product). If 174 parental MVA-LZ virus remained at this stage, the chimeras were subjected to 175 plaque purification. Some chimeras made with 8 kbp FWPV inserts returned PCR 176 products shorter than expected, or no products at all. Such viruses were not 177 further characterised but were labelled as "unstable". The sensitivity of FWPV FP9 replication to exogenous ChIFN was measured by 294 plaque reduction on primary chicken embryo fibroblasts (CEF) in the presence of 295 recombinant ChIFN1. In our preliminary studies in CEF, the IC50 for the control 296 virus, Semliki Forest virus (SFV) A7(74), was by definition, 1 U ml -1 , while that 297 for VACV WR (VTN) was 176 U ml -1 (Fig. 1) . VACV MVA, which was derived by 298 extensive CEF passages (more than 500), during which it underwent 299 considerable deletion of genomic sequences relative to its parental strain, 300 chorioallantois Vaccinia virus Ankara (35-37), had an IC50 of only 7 U ml -1 . FP9, 301 however, proved far more resistant (Fig. 1) , such that the number of plaques was 302 reduced only by 36 % at the highest concentration of ChIFN used (1563 U ml -1 ). 303
The ChIFN used in this preliminary study caused some cytotoxicity at high 304 concentrations (Fig. 1A) , so the IC50 for FP9 could initially only be estimated 305 upon extrapolation by non-linear regression, yielding a tentative figure of 2570 U 306 ml -1 . 307 308 Identification of FWPV chimeric MVA with enhanced resistance to ChIFN1. 309
The observation that MVA is almost 400-fold more sensitive to the antiviral 310 effects of ChIFN1 than FP9 ( were isolated following separate transfections with fragment 50. Chimeras MVA-333 f50a and MVA-f50c but not "unstable" chimera MVA-f50b nor control chimera 334 MVA-fC2b showed strong expression of fpv191 (Fig. 2b) . 335 336 A total of 28 of the chimeras (none of which were classified as "unstable") were 337 screened, by plaque reduction assay, for enhanced resistance to low titres of 338 ChIFN1 (10 to 16 U ml -1 ). Data from the screening of 18 such chimeras are shown 339 in Fig. 3 . Chimera MVA-f3La was readily identified as having significantly higher 340 resistance than the control and other chimeras, whether screened as third bulk-341 passage (Fig. 3a) or plaque-purified (Fig. 3b) FWPV genes were expressed at higher levels from the chimera than from donor 356 FP9 (Fig. 4) (Fig. 4) . 361
362
The single gene recombinant MVA were similarly screened for enhanced 363 resistance to ChIFN1 by plaque reduction assay. Preliminary experiments (for 364 example Fig. 5a ) showed that fpv013 did not contribute to enhanced ChIFN1 365 resistance. Subsequent experiments demonstrated that plaque formation by 366 MVA-f3La, under different concentrations of ChIFN1, was significantly higher 367 than that by the control MVA-fC2a and the recombinant (MVA-F.012) expressing 368 only fpv012 but not the recombinant (MVA-F.014) expressing only fpv014 (Fig.  369 5b and c). MVA-F.014 consistently plaqued at considerably higher efficiency than 370 MVA-fC2a and MVA-F.012 but the results did not reach statistical significance. 371
The IC50 of ChIFN1 for each of the viruses was therefore derived in a further 372 experiment. The IC50 for MVA-f3La (68 U ml -1 ) was significantly higher than 373 those for MVA-fC2a (25 U ml -1 ) and MVA-F.012 (18 U ml -1 ). Although that forMVA-F.014 (41 U ml -1 ) was not significantly higher than that for MVA-fC2a, it 375 was significantly higher than that for MVA-F.012 (Fig. 5d) . It is therefore only 376 fpv014 that consistently shows a contribution towards the resistance to ChIFN1 377 observed in MVA-f3La. 378 379 Expression of fpv014 by FWPV. 380
Analysis of fpv014 mRNA expression by qRT-PCR revealed that its levels and 381 kinetics in CEF infected with parental FWPV FP9 are comparable to those of 382 fpv100 (Fig. 6a) , with expression clearly detectable at 2h (in contrast to late gene 383 fpv168) and increasing to 8h in an AraC-sensitive manner (though in contrast to 384 the highly expressed late gene fpv168, low level expression is still detectable in 385 the presence of AraC). Gene fpv100 is an ortholog of VACV E4L (VACWR060), 386 which encodes RNA polymerase subunit RPO30 and shows group E1.1 387 expression kinetics (39). 388 389 Antibodies for fpv014 are still unavailable but a TAP-tagged version of the gene 390 was inserted back into the native locus under control of the cognate promoter 391 and its expression was demonstrated by western blotting of lysates with anti-392 FLAG antibodies (Fig. 6b) . ChIFN1 for the fpv014-knockout virus was therefore derived in comparison with 409 that for parental FP9 (Fig. 7B ) using ChIFN1 that did not cause the cytotoxicity 410 seen in the preliminary study (Fig. 1A) , so that the IC50 did not have to be 411 calculated by extrapolation. At 2008 U ml -1 , the IC50 for the fpv014-knockout 412 virus proved to be significantly different to that for parental FP9 (5564 U ml -1 ). (Fig. 8c) . In the purified 452 eluates from TAP-fpv014 expressing cells, some Skp1 was evident at 19 kDa, but 453 most of it co-migrated (at 72 kDa) with the slower migrating pair of TAP-tagged 454 fpv014 bands (Fig. 8c) . Immunoblotting also detected cullin-1 in the control 455 lysates, at the expected size of 90 kDa (Fig. 8c) . The cullin-1 in the purified 456 eluates from TAP-fpv014 expressing cells, however, migrated slightly slower 457 than in the control lysates (consistent with the 98 kDa ubiquitinated form of 458
Cullin-1 observed to interact with the myxoma virus PRANC protein MNF (41) we have no reason to expect that HP-1 fpv014 should be any more effective than 528 that of FP9. Apart from FWPV, the only other member of the Avipoxvirus genus 529 for which the genome sequence has been published is CNPV, which is 530 considerably diverged from FWPV, displays significant differences in gene 531 complement (10, 11) and is found in a different major clade of the genus (58). 532
Comparisons between ANK proteins can be problematic but Sonnberg et al. (55) Despite considerable effort, we have been unable to identify a cellular ligand for 553 the N-terminal ANK domain of fpv014. Although it was not our main goal, we 554 were able to demonstrate tandem affinity co-purification of chicken cullin-1 (by 555 mass spectrometry and immunoblotting) and chicken Skp1 (by immunoblotting 556 only) with TAP-tagged fpv014. This indicated that fpv014 interacts with the 557 avian ubiquitin ligase complex (presumably via the F-box) in the same way that 558 PRANC proteins of mammalian poxviruses have been shown to interact with the 559 mammalian complexes. The immunoblotting was performed after non-reducing 560 SDS-PAGE, not to look for complexes but for compatibility with subsequent mass 561 spectrometry. The observation that most of the co-purified Skp1 co-migrated 562 with a substantial proportion of the TAP-tagged fpv014 was, therefore, 563 somewhat serendipitous. However, it suggests that fpv014 and chicken Skp1 can 564 form an SDS-stable complex. Unfortunately, we were not able to further 565 investigate whether the complex was reductant-sensitive. We are not aware of 566 reports of similar F-box protein:Skp1 gel complexes (though such complexes are 567 observed elsewhere (65, 66)), nor is it apparent to us that others in the field have 568 looked directly for such a complex, or have been in a position to observe it. The 569 cullin-1 that co-purified with TAP-tagged fpv014, however, does not appear to 570 form a co-migrating complex with it on the immunoblot. Because the interaction 571 of cullin-1 with F-box proteins is indirect, via Skp1, it is not perhaps not 572
surprising that an fpv014:cullin-1 complex should be less stable than an 573 fpv014:Skp1 complex. Although the cullin-1 that co-purified with TAP-tagged 574 fpv014 did not form a complex with the fpv014 on the immunoblot, it migrated 575 more slowly than the cullin-1 in the control lysate. There is a precedent for this 576 observation in that two similar size bands co-purified with GFP-tagged myxoma 577 virus MNF protein. The predominant slower form immunoblotted with an 578 unspecified anti-ubiquitin antibody (41). There is no indication at this stage 579 whether fpv014 stabilised the modified form of cullin-1 in the cell, or whether it 580 was solely (or predominantly) the modified form that co-purified with TAP-581 tagged fpv014. We have not been able to investigate whether the cullin-1 that co-582 purified with TAP-tagged fpv014 was ubiquitinated, but we are aware that the 583 size difference observed between it and the cullin-1 from control lysates could 584 equally correspond to the well-reported addition of the ubiquitin-like NEDD8 585 adduct, rather than ubiquitin itself (67) (68) (69) . 586 Control lysate TAP-a nity-puri ed eluate Control lysate TAP-a nity-puri ed eluate Control lysate TAP-a nity-puri ed eluate
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